---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023296"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:51:47.849944+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cyclacel faces going concern warning; cash of $3.45M expected only into Q2 2025

## Summary
- Auditor expresses substantial doubt about Cyclacel's ability to continue as a going concern; cash of $3.45M at March 31, 2025, expected to fund only into Q2 2025.
- Net loss of $81k for Q1 2025 vs $2.9M in Q1 2024, largely due to a $4.9M gain from deconsolidation of UK subsidiary Cyclacel Limited on Jan 24, 2025.
- Operating loss of $5.0M; R&D expenses fell to $822k from $2.8M, while G&A rose to $4.2M from $1.6M, partly due to $1.7M stock-based compensation.
- Issued Series D and E preferred stock and converted shares; common shares outstanding surged from 8.9M to 207.3M during Q1 2025.
- Regained Nasdaq compliance with equity rule on Feb 25, 2025; subject to one-year mandatory panel monitor.

## SEC filing metadata
- accession: 0001641172-25-023296
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000164117225023296/0001641172-25-023296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000164117225023296/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023296
- JSON: https://secwatch.observer/filing/0001641172-25-023296.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.